Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 5/20 | 0.34 |
| ▸ | MMP9 | P14780 | 5/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.31 |
| ▸ | LIPC | P11150 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480489 | 0.78 | SNCA (0.47) | POLBP2RY14 | |
| SCHEMBL3480501 | 0.74 | MAPT (0.48) | KMT2AMEN1MMP2MMP9MMP13 | |
| SCHEMBL3480434 | 0.73 | MMP13 (0.45) | KMT2APOLBMEN1MMP2MMP9 | |
| SCHEMBL4427998 | 0.70 | SMN1; SMN2 (0.55) | KMT2AMEN1RAB9A | |
| SCHEMBL16667405 | 0.70 | P2RY14 (0.38) | MAP3K5MMP2MMP9P2RY14MMP13 | |
| SCHEMBL3480416 | 0.69 | MAP3K5 (0.35) | KMT2APOLBMEN1PKMRAB9A | |
| SCHEMBL3480347 | 0.65 | MCL1 (0.41) | KMT2AMEN1RAB9A | |
| SCHEMBL3483578 | 0.63 | L3MBTL1 (0.38) | KMT2AMEN1 | |
| SCHEMBL1864479 | 0.63 | RAB9A (0.57) | KMT2APOLBMEN1RAB9A | |
| SCHEMBL4430974 | 0.63 | CYP2D6 (0.64) | KMT2APOLBPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | claimed |
| EP-2024376-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007139729-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2007-12-06 | — | — | WO | claimed |
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | 92229129 QUEBEC INC. (CA) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317625-A1 | NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE | MGAM, BPGM, PPME1 | ATIC 387/4885RORC 3260/4885KMT2A 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.